BeOne Medicines (ONC)
NASDAQ:ONC
Want to see ONC full AI Analyst Report?
Total Valuation
BeOne Medicines has a market cap or net worth of $34.33B. The enterprise value is $35.92B.
Market Cap$34.33B
Enterprise Value$35.92B
Share Statistics
BeOne Medicines has 109,720,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding109,720,300
Owned by Insiders68.05%
Owned by Institutions12.71%
Financial Efficiency
BeOne Medicines’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 4.74%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.74%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee485.73K
Profits Per Employee26.08K
Employee Count11,000
Asset Turnover0.65
Inventory Turnover1.10
Valuation Ratios
The current PE Ratio of BeOne Medicines is 36.2. BeOne Medicines’s PEG ratio is -0.18.
PE Ratio36.2
PS Ratio6.20
PB Ratio7.60
Price to Fair Value7.60
Price to FCF35.18
Price to Operating Cash Flow41.25
PEG Ratio-0.18
Income Statement
In the last 12 months, BeOne Medicines had revenue of 5.34B and earned 286.93M in profits. Earnings per share was 33.80.
Revenue5.34B
Gross Profit4.67B
Operating Income447.14M
Pretax Income416.85M
Net Income286.93M
EBITDA616.77M
Earnings Per Share (EPS)33.80
Cash Flow
In the last 12 months, operating cash flow was 1.29B and capital expenditures -438.89M, giving a free cash flow of 846.54M billion.
Operating Cash Flow1.29B
Free Cash Flow846.54M
Free Cash Flow per Share7.72
Dividends & Yields
BeOne Medicines pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.78
52-Week Price Change25.67%
50-Day Moving Average314.45
200-Day Moving Average318.12
Relative Strength Index (RSI)62.73
Average Volume (3m)206.71K
Important Dates
BeOne Medicines upcoming earnings date is Aug 21, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
BeOne Medicines as a current ratio of 3.41, with Debt / Equity ratio of 43.13%
Current Ratio3.41
Quick Ratio3.08
Debt to Market Cap0.06
Net Debt to EBITDA-4.13
Interest Coverage Ratio7.68
Taxes
In the past 12 months, BeOne Medicines has paid 129.92M in taxes.
Income Tax129.92M
Effective Tax Rate0.31
Enterprise Valuation
BeOne Medicines EV to EBITDA ratio is 49.59, with an EV/FCF ratio of 32.48.
EV to Sales5.72
EV to EBITDA49.59
EV to Free Cash Flow32.48
EV to Operating Cash Flow27.13
Balance Sheet
BeOne Medicines has $4.79B in cash and marketable securities with $1.15B in debt, giving a net cash position of $3.64B billion.
Cash & Marketable Securities$4.79B
Total Debt$1.15B
Net Cash$3.64B
Net Cash Per Share$33.20
Tangible Book Value Per Share$39.41
Margins
Gross margin is 87.17%, with operating margin of 8.37%, and net profit margin of 5.37%.
Gross Margin87.17%
Operating Margin8.37%
Pretax Margin7.80%
Net Profit Margin5.37%
EBITDA Margin11.54%
EBIT Margin8.89%
Analyst Forecast
The average price target for BeOne Medicines is $388.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$388.58
Price Target Upside19.98% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast37.70%
EPS Growth Forecast―